Wednesday, 16 Sep 2026
Empowering Chinese Pharma’s Global Expansion
Contact US
Home
About US
Policy Hub
Categories
Drug
Company
Deals
Policy / Regulatory
Medical Device
R&D
Legal / IP
Digital
Privacy Policy
Contact US
My News
Cancer
Clinical trial approval / initiation
Product approvals
Clinical trial results
Finance
ADC / XDC
Finanical Reports
Biotech
Market approval filings
PD-1/L1
Read History
Search
Pages
Home
Blog Index
POLICY HUB
Contact Us
Personalized
Read History
Categories
Company
Drug
Policy / Regulatory
Medical Device
R&D
Digital
Legal / IP
Deals
Have an existing account?
Sign In
Follow US
Fineline Cube
Follow:
14398
Articles
Company
Deals
MicuRx Pharmaceuticals Approved for STAR Market IPO by CSRC
February 25, 2025
Company
Drug
Innovent Biologics’ Pemazyre Becomes First FGFR2 Inhibitor Approved in China
February 25, 2025
Company
Drug
Dizal Pharma’s DZD1516 Receives NMPA Green Light for HER2+ Breast Cancer Trial
February 25, 2025
Company
Deals
WuXi XDC Partners with AbTis to Advance ADC Development and Manufacturing
February 25, 2025
Company
Drug
GenScript Biotech’s Legend Biotech Terminates LB1901 CAR-T Phase I Trial
February 25, 2025
Company
Deals
ClouDr Group’s Hong Kong IPO Nets HKD 482 Million with Sanofi as Investor
February 27, 2025
Company
Deals
Baifu Laser Raises RMB 100 Million in Series A Funding for Optoelectronic Equipment
February 27, 2025
Company
Medical Device
Oriomics Launches XiaoWeiAn Multi-Tumor Early Screening Product
February 27, 2025
Company
Drug
Zhaoke Ophthalmology Enrolls First Patient in TAB014 Phase III Study for wAMD
February 27, 2025
Company
Deals
GeneRulor Medical Technology Raises Funds for Gene Editing Diagnostics
February 27, 2025
Company
Drug
Brii Biosciences Launches Anti-COVID-19 Antibody Cocktail in China
February 27, 2025
Company
Drug
Junshi Biosciences’ PD-1 Inhibitor Tuoyi Under FDA Review for NPC Treatment
February 27, 2025
1
2
…
1,177
1,178
1,179
1,180
1,181
…
1,199
1,200
Welcome to Fineline Cube!
Username or Email Address
Password
Remember me
Lost your password?